42
|
111
|
7ko0A |
Crystal structure of the second bromodomain (bd2) of human brd4 bound to sg3-179 |
42
|
125
|
7p6vAAA |
N-terminal bromodomain of human brd4 with compound 3ag |
40
|
126
|
7p6yAAA |
N-terminal bromodomain of human brd4 with compound 5ef |
40
|
127
|
7p6wAAA |
N-terminal bromodomain of human brd4 with compound 3bg |
42
|
124
|
7o18AAA |
N-terminal bromodomain of human brd4 with i-bet282 |
40
|
126
|
7mceA |
Crystal structure of the first bromodomain of human brd4 in complex with 2-{(7p)-7-(1,4-dimethyl-1h-1,2,3-triazol-5-yl)-8-fluoro-5-[(s)-(oxan-4-yl)(phenyl)methyl]-5h-pyrido[3,2-b]indol-3-yl}propan-2-ol |
44
|
123
|
7m16A |
Triazole-based bet family bromodomain inhibitor bound to brd4(d1) |
41
|
127
|
7k6gA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to erk5-in-1 |
41
|
127
|
7k6hA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to xmd8-92 |
41
|
127
|
7jkyA |
Bromodomain-containing protein 4 (brd4) bromodomain 1 (bd1) complexed with yf3-126 |
40
|
111
|
7jkzA |
Bromodomain-containing protein 4 (brd4) bromodomain 2 (bd2) complexed with yf3-126 |
42
|
127
|
7jkwA |
Bromodomain-containing protein 4 (brd4) bromodomain 1 (bd1) complexed with zn1-99 |
47
|
129
|
7dhsA |
Crystal structure analysis of the brd4 |
42
|
127
|
7axrA |
Crystal structure of brd4(1) bound to the dual bet-hdac inhibitor lsh24 |
43
|
126
|
6wvxA |
Crystal structure of the first bromodomain of human brd4 with benzodiazepine inhibitor |
42
|
126
|
5s9rA |
Crystal structure of the first bromodomain of human brd4 in complex with bms-986158, 2-{3-(1,4-dimethyl-1h-1,2,3-triazol-5-yl)-5-[(s)-(oxan-4-yl)(phenyl)methyl]-5h-pyrido[3,2-b]indol-7-yl}propan-2-ol |
44
|
127
|
5s9qA |
Crystal structure of the first bromodomain of human brd4 in complex with 2-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxypropan-2-yl)-9-[(s)-(oxan-4-yl)(phenyl)methyl]-9h-carbazole-4-carboxamide |
43
|
128
|
5s9pA |
Crystal structure of the first bromodomain of human brd4 in complex with 9-benzyl-2-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxypropan-2-yl)-9h-carbazole-4-carboxamide |
43
|
127
|
7remA |
Crystal structure of the first bromodomain (bd1) of human brd4 in complex with dual brd4-jak2 inhibitor pn1-050 |
44
|
125
|
7rekA |
Crystal structure of the first bromodomain (bd1) of human brd4 in complex with dual brd4-jak2 inhibitor ma9-086 |
45
|
127
|
7relA |
Crystal structure of the first bromodomain (bd1) of human brd4 in complex with dual brd4-jak2 inhibitor ma9-060 |
41
|
111
|
7oeoAAA |
C-terminal bromodomain of human brd4 n-(2,2-diphenylethyl)-4-methoxy-3,5-dimethyl-n-(2-(methylamino)-2-oxoethyl)benzamide |
42
|
126
|
7mlqA |
X-ray crystal structure of human brd4(d1) in complex with 2-(4-{5-[6-(2,5-dibromophenoxy)pyridin-2-yl]-4-methyl-1h-1,2,3-triazol-1-yl}piperidin-1-yl)-n,n-dimethylethan-1-amine (compound 26) |
43
|
126
|
7mlsA |
X-ray crystal structure of human brd4(d1) in complex with 2-(2,5-dibromophenoxy)-6-[4-methyl-1-(piperidin-4-yl)-1h-1,2,3-triazol-5-yl]pyridine (compound 23) |
43
|
126
|
7mlrA |
X-ray crystal structure of human brd4(d1) in complex with 2-(4-{5-[6-(3,5-dimethylphenoxy)pyridin-2-yl]-4-methyl-1h-1,2,3-triazol-1- yl}piperidin-1-yl)-n,n-dimethylethan-1-amine (dw34) |
41
|
127
|
7jkxA |
Bromodomain-containing protein 4 (brd4) bromodomain 1 (bd1) complexed with yf3-6 |
32
|
108
|
7mcfA |
Crystal structure of the first bromodomain of human brd4 in complex with 2-{3-(1,4-dimethyl-1h-1,2,3-triazol-5-yl)-6-fluoro-5-[(s)-(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-5h-pyrido[3,2-b]indol-7-yl}propan-2-ol |
36
|
105
|
7c6pA |
Bromodomain-containing 4 bd2 in complex with 3',4',7,8- tetrahydroxyflavonoid |
46
|
125
|
7c2zA |
Bromodomain-containing 4 bd1 in complex with 3',4',7,8-tetrahydroxyflavone |
44
|
127
|
6yqzA |
N-terminal domain of brd4 with biphenyl-methyamino-dimethylpyridazinone |
44
|
126
|
7khlA |
Brd4-bd1 compound6 (methyl 4-(3,5-difluoropyridin-2-yl)-10-methyl-7-((methylsulfonyl)methyl)-11-oxo-3,4,10,11-tetrahydro-1h-1,4,10-triazadibenzo[cd,f]azulene-6-carboxylate) |
44
|
127
|
6zb3AAA |
N-terminal bromodomain of human brd4 with gsk620 |
42
|
127
|
6x7cA |
Brd4 bromodomain 1 in complex with multi-action inhibitor srx3212 |
37
|
124
|
6x7dA |
Brd4 bromodomain 1 in complex with multi-action inhibitor sf2523p |
43
|
134
|
6x7bA |
Brd4 bromodomain 1 in complex with multi-action inhibitor srx3212p |
44
|
127
|
6sajA |
Crystal structure of brd4(1) bound to inhibitor bux6 (12) |
41
|
124
|
6lg5A |
Crystal structure of the first bromodomain of human brd4 in complex with compound bdf-1038 |
43
|
124
|
6limA |
Brd4-bd1 bound with compound 40 |
42
|
124
|
6lihA |
Brd4 bd1 bound with compound 10 |
44
|
124
|
6lg7A |
Crystal structure of the first bromodomain of human brd4 in complex with compound bdf-2030 |
42
|
124
|
6lg4A |
Crystal structure of the first bromodomain of human brd4 in complex with compound bdf-1024 |
42
|
124
|
6lg6A |
Crystal structure of the first bromodomain of human brd4 in complex with compound bdf-1021 |
42
|
124
|
6lg8A |
Crystal structure of the first bromodomain of human brd4 in complex with compound bdf-2138 |
45
|
127
|
7a9uAAA |
N-terminal bromodomain of human brd4 with 3-(3-(but-3-yn-1-yl)-3h-diazirin-3-yl)-n-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propanamide |
44
|
127
|
7ajnA |
Crystal structure of the first bromodomain of brd4 in complex with a bzd ligand |
45
|
127
|
6rwjA |
Crystal structure of brd4(1) bound to inhibitor bug0 (6) |
1
|
14
|
6ulvE |
Brd4-bd1 in complex with the cyclic peptide 4.2_1 |
37
|
109
|
6sa3A |
Crystal structure of brd4(1) bound to inhibitor bux4 (13) |
44
|
127
|
6s6kA |
Crystal structure of brd4(1) bound to inhibitor bux2 (9) |
36
|
108
|
6ulvA |
Brd4-bd1 in complex with the cyclic peptide 4.2_1 |